Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options
Rhea-AI Filing Summary
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KANGO SUJAY
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,090 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,090 shares (Direct)
Footnotes (1)
- F1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Key Figures
Option grant size: 6,090 options
Exercise price: $89.63 per share
Underlying shares: 6,090 shares
+2 more
5 metrics
Option grant size
6,090 options
Stock Option (Right to Buy) granted to director Sujay Kango
Exercise price
$89.63 per share
Conversion or exercise price of granted stock options
Underlying shares
6,090 shares
Common stock underlying the new option award
Expiration date
May 21, 2036
Option term end date for the 6,090-share grant
Post-grant derivative holdings
6,090 options
Total derivative securities held following this transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, vesting, Annual Meeting of Stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vesting financial
"shares of common stock underlying this stock option award will vest in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting of Stockholders financial
"earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Sujay Kango acquire in this Dianthus Therapeutics (DNTH) Form 4 filing?
Sujay Kango received a grant of stock options for 6,090 shares of Dianthus Therapeutics common stock. These options are a form of equity compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.
What is the exercise price of Sujay Kango’s new Dianthus Therapeutics options?
The granted options have an exercise price of $89.63 per share. This means Kango can buy Dianthus Therapeutics common stock at $89.63 for each of the 6,090 underlying shares once the options vest and before they expire on May 21, 2036.
When do Sujay Kango’s Dianthus Therapeutics stock options vest?
All 6,090 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Vesting is conditional on Kango’s continued service to Dianthus Therapeutics through the applicable vesting date.
When do Sujay Kango’s newly granted Dianthus Therapeutics options expire?
The stock options granted to Sujay Kango expire on May 21, 2036. After that expiration date, any unexercised portion of the 6,090-share option grant can no longer be used to purchase Dianthus Therapeutics common stock at the specified exercise price.
How many derivative securities does Sujay Kango hold after this Dianthus Therapeutics grant?
Following this grant, Sujay Kango holds 6,090 derivative securities in the form of stock options. Each option corresponds to one share of Dianthus Therapeutics common stock, giving him future purchase rights at the fixed exercise price if the options are exercised.